Invention Grant
- Patent Title: Bilirubin derivative-based diagnostic and therapeutic ultrasound contrast agent
-
Application No.: US16985219Application Date: 2020-08-04
-
Publication No.: US11571486B2Publication Date: 2023-02-07
- Inventor: Sang Yong Jon , Dong Yun Lee , Yong Hyun Lee , Jin Yong Kim
- Applicant: Bilix Co., Ltd.
- Applicant Address: KR Seoul
- Assignee: Bilix Co., Ltd.
- Current Assignee: Bilix Co., Ltd.
- Current Assignee Address: KR Seoul
- Agency: The PL Law Group, PLLC
- Priority: KR10-2018-0014160 20180205
- Main IPC: A61K9/50
- IPC: A61K9/50 ; A61K31/136 ; A61K49/18 ; A61K33/243 ; A61K31/282 ; A61K31/337 ; A61K31/704 ; A61K31/7068 ; A61K49/22

Abstract:
Provided is a bilirubin derivative-based ultrasound contrast agent for diagnosis and treatment. The fine particles including the bilirubin derivative are sensitive to reactive oxygen species (ROS), bind with hydrophobic drugs, and can effectively chelate metals such as iron oxide nanoparticles. Therefore, the fine particle of the present invention can be used as an ultrasound contrast agent for diagnosis, as a magnetic resonance imaging contrast agent, or as a carrier for hydrophobic drugs or platinum-based drugs.
Public/Granted literature
- US20210030897A1 BILIRUBIN DERIVATIVE-BASED DIAGNOSTIC AND THERAPEUTIC ULTRASOUND CONTRAST AGENT Public/Granted day:2021-02-04
Information query